Celularity Inc.
$1.24
▲
1.53%
2026-04-21 05:58:01
www.celularity.com
NCM: CELU
Explore Celularity Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$35.47 M
Current Price
$1.24
52W High / Low
$4.35 / $1.01
Stock P/E
—
Book Value
$-0.71
Dividend Yield
—
ROCE
-48.8%
ROE
-232.51%
Face Value
—
EPS
$-3.33
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
123
Beta
0.7
Debt / Equity
7.79
Current Ratio
0.16
Quick Ratio
0.28
Forward P/E
-2.23
Price / Sales
0.9
Enterprise Value
$102.62 M
EV / EBITDA
-2.48
EV / Revenue
2.53
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Propanc Biopharma, Inc. | $0.12 | — | $2.33 M | — | -407.57% | -18.12% | $11 / $0.1 | $0.78 |
| 2. | CG Oncology, Inc. | $70.4 | — | $6.2 B | — | -25.08% | -21.67% | $73.56 / $19.47 | $9.33 |
| 3. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 4. | Plus Therapeutics, Inc. | $7.3 | — | $50.09 M | — | -381.4% | 903.94% | $30.5 / $2.9 | $0.72 |
| 5. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
| 6. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 7. | Clearmind Medicine Inc. | $1.14 | — | $2.38 M | — | -475.2% | -1.2% | $52.4 / $0.59 | $5.49 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 5.28 M | 5.74 M | 11.43 M | 18.13 M | 9.3 M |
| Operating Profit | -12.9 M | -15.86 M | -10.49 M | -9.47 M | -11.53 M |
| Net Profit | -23.08 M | -24.52 M | -19.75 M | -13.29 M | -16.1 M |
| EPS in Rs | -0.8 | -0.85 | -0.69 | -0.46 | -0.56 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 54.22 M | 22.77 M | 17.98 M | 21.34 M |
| Operating Profit | -38.55 M | -76.48 M | -148.27 M | -150.2 M |
| Net Profit | -57.89 M | -196.29 M | 14.19 M | -100.12 M |
| EPS in Rs | -2.01 | -6.81 | 0.49 | -3.47 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 132.68 M | 143.89 M | 401.07 M | 414.13 M |
| Total Liabilities | 123.84 M | 102.93 M | 202.16 M | 314.71 M |
| Equity | 8.84 M | 40.96 M | 198.9 M | 99.42 M |
| Current Assets | 20.56 M | 19.79 M | 33.5 M | 59.1 M |
| Current Liabilities | 53.68 M | 67.3 M | 62.09 M | 26.23 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -6.4 M | -38.69 M | -137.88 M | -110.1 M |
| Investing CF | 0.51 M | -4.05 M | -5.24 M | -5.9 M |
| Financing CF | 6.7 M | 24.09 M | 119.84 M | 98.56 M |
| Free CF | -6.56 M | -42.73 M | -143.11 M | -116.3 M |
| Capex | -0.16 M | -4.05 M | -5.24 M | -6.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 138.11% | 26.68% | -15.75% | — |
| Earnings Growth % | 70.51% | -1483.14% | 114.18% | — |
| Profit Margin % | -106.77% | -862.04% | 78.95% | -469.27% |
| Operating Margin % | -71.1% | -335.86% | -824.85% | -704.03% |
| Gross Margin % | 72.36% | 29.66% | -9.4% | 54.76% |
| EBITDA Margin % | -80.61% | -807.81% | 131.52% | -412.98% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-02-29 | 1:0.1 |